ANAPTYSBIO, INC 8-K

What Happened
AnaptysBio, Inc. announced its financial results for the three months ended March 31, 2026 via a press release and disclosed the release in a Current Report on Form 8-K filed May 12, 2026 (Item 2.02). The press release summarizing the company’s quarterly results is included as Exhibit 99.1 to the Form 8-K. The filing was signed by Chief Financial Officer Christopher M. Murphy.

Key Details

• Filing date: May 12, 2026 (Form 8-K filed with the SEC).
• Reported period: three months ended March 31, 2026.
• Exhibit: Press release attached as Exhibit 99.1 containing the company’s quarterly financial results.
• Signature: Form 8-K executed by Christopher M. Murphy, Chief Financial Officer.

Why It Matters
This filing formally notifies investors that AnaptysBio released its quarterly earnings information; the attached press release is the primary source for revenue, earnings, cash position, and any management commentary or guidance. Retail investors should read Exhibit 99.1 to see the specific financial figures and any business updates that could affect the stock.